Pfizer (PFE) EBT (2009 - 2026)

Pfizer (PFE) has 18 years of EBT data on file, last reported at $3.2 billion in Q1 2026.

• EBT for Q1 2026 came in at $3.2 billion, up 13.82% year-over-year; the trailing twelve-month figure through Mar 2026 was $7.9 billion (down 26.92% YoY), and the FY2025 annual result was $7.5 billion, down 6.27% from the prior year.
• EBT improved to $3.2 billion in Q1 2026 per PFE's latest filing, from -$1.6 billion in the prior quarter.
• Over five years, EBT peaked at $11.4 billion in Q3 2022 and troughed at -$4.1 billion in Q4 2023.
• A 5-year average of $3.3 billion and a median of $3.2 billion in 2026 frame the typical range for EBT.
• The sharpest annual moves came in 2023 and 2025: EBT tumbled 137.24% in 2023, then soared 3055.34% in 2025.
• A 5-year view of EBT shows it stood at $9.0 billion in 2022, then plunged by 145.87% to -$4.1 billion in 2023, then jumped by 214.19% to $4.7 billion in 2024, then plunged by 134.83% to -$1.6 billion in 2025, then soared by 293.06% to $3.2 billion in 2026.
• Business Quant data shows PFE's EBT at $3.2 billion in Q1 2026, -$1.6 billion in Q4 2025, and $3.3 billion in Q3 2025.